Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for protein-protein interfaces.
Fig. 1. The sreening workflow of Receptor.AI
It includes extensive molecular simulations of the target alone and in complex with its most relevant partner proteins, followed by ensemble virtual screening that accounts for conformational mobility in free and bound forms. The tentative binding pockets are considered on the protein-protein interface itself and in remote allosteric locations in order to cover the whole spectrum of possible mechanisms of action.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q13009
UPID:
TIAM1_HUMAN
Alternative names:
T-lymphoma invasion and metastasis-inducing protein 1
Alternative UPACC:
Q13009; B7ZLR6; F5GZ53; Q17RT7
Background:
Rho guanine nucleotide exchange factor TIAM1, also known as T-lymphoma invasion and metastasis-inducing protein 1, plays a pivotal role in cellular processes by activating RHO-like proteins. It primarily activates RAC1, CDC42, and to a lesser extent RHOA, facilitating cell adhesion and migration through its guanyl-nucleotide exchange factor activity.
Therapeutic significance:
TIAM1's involvement in neurodevelopmental disorder with language delay and seizures highlights its potential as a therapeutic target. Understanding the role of TIAM1 could open doors to potential therapeutic strategies for treating such neurodevelopmental disorders.